Brookline Capital Markets Expects Lower Earnings for Genelux

Posted by Stanley Muller on May 12th, 2026

Genelux Corporation (NASDAQ:GNLX – Free Report) – Investment analysts at Brookline Capital Markets decreased their Q2 2026 earnings per share estimates for shares of Genelux in a research report issued on Thursday, May 7th. Brookline Capital Markets analyst K. Dolliver now forecasts that the company will post earnings per share of ($0.19) for the quarter, down from their previous forecast of ($0.17). The consensus estimate for Genelux’s current full-year earnings is ($0.74) per share. Brookline Capital Markets also issued estimates for Genelux’s Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.20) EPS and FY2026 earnings at ($0.79) EPS.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genelux in a report on Tuesday, April 21st. Wall Street Zen cut shares of Genelux from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Finally, Benchmark lowered their price target on shares of Genelux from $23.00 to $20.00 and set a “speculative buy” rating on the stock in a report on Friday, March 20th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Check Out Our Latest Stock Report on Genelux

Genelux Stock Down 6.8%

Shares of NASDAQ GNLX opened at $2.90 on Tuesday. Genelux has a twelve month low of $2.29 and a twelve month high of $8.53. The stock’s 50 day moving average price is $2.65 and its 200-day moving average price is $3.70. The company has a market capitalization of $130.04 million, a PE ratio of -3.41 and a beta of 0.51.

Genelux (NASDAQ:GNLX – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02).

Insider Transactions at Genelux

In related news, Director John Thomas sold 10,000 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $2.90, for a total value of $29,000.00. Following the completion of the transaction, the director directly owned 482,784 shares of the company’s stock, valued at $1,400,073.60. This represents a 2.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 7.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Genelux

A number of institutional investors have recently bought and sold shares of GNLX. Jefferies Financial Group Inc. purchased a new stake in shares of Genelux in the 4th quarter worth approximately $48,000. Squarepoint Ops LLC bought a new stake in shares of Genelux during the fourth quarter valued at approximately $52,000. Balyasny Asset Management L.P. purchased a new stake in Genelux in the fourth quarter worth approximately $94,000. Align Financial LLC purchased a new stake in Genelux in the fourth quarter worth approximately $123,000. Finally, Raymond James Financial Inc. boosted its holdings in Genelux by 22.6% in the second quarter. Raymond James Financial Inc. now owns 28,933 shares of the company’s stock worth $83,000 after purchasing an additional 5,333 shares during the last quarter. 37.33% of the stock is owned by institutional investors.

Key Genelux News

Here are the key news stories impacting Genelux this week:

Negative Sentiment: HC Wainwright lowered its FY2026 EPS estimate for Genelux to a loss of $0.81 per share from $0.79, signaling a slightly weaker full-year profit outlook. Genelux stock and analyst coverage
Negative Sentiment: Brookline Capital Markets cut its FY2026 EPS estimate to a loss of $0.79 per share from $0.69, another sign that analysts expect deeper losses than previously modeled. Genelux stock and analyst coverage
Negative Sentiment: Brookline also reduced Q2 2026 and Q3 2026 EPS estimates to losses of $0.19 and $0.20, respectively, while HC Wainwright trimmed Q4 2026 expectations to a $0.20 loss, reinforcing the view that profitability remains distant. Genelux stock and analyst coverage
Neutral Sentiment: HC Wainwright slightly raised its Q3 2026 EPS estimate to a $0.20 loss from $0.21, a modest change that does not materially alter the broader negative earnings picture. Genelux stock and analyst coverage
Neutral Sentiment: Short-interest data showed no meaningful change in the share count, so it is unlikely to be a major driver of trading today. Genelux stock short interest

Genelux Company Profile

(Get Free Report)

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.